177 related articles for article (PubMed ID: 29271956)
1. [Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies].
Deyev SM; Lebedenko EN
Mol Biol (Mosk); 2017; 51(6):907-926. PubMed ID: 29271956
[TBL] [Abstract][Full Text] [Related]
2. [Engineering Antibodies as Drugs: Principles and Practice].
Lugovskoy AA
Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
[TBL] [Abstract][Full Text] [Related]
3. [Next-Generation Techniques for Discovering Human Monoclonal Antibodies].
Lushova AA; Biazrova MG; Prilipov AG; Sadykova GK; Kopylov TA; Filatov AV
Mol Biol (Mosk); 2017; 51(6):899-906. PubMed ID: 29271955
[TBL] [Abstract][Full Text] [Related]
4. [Antibody-Based Drugs and Other Recombinant Proteins for Diagnostics and Therapy of Viral Infections, Autoimmune Diseases and Cancer].
Kuprash DV; Garib FY; Nedospasov SA
Mol Biol (Mosk); 2017; 51(6):883-885. PubMed ID: 29271953
[No Abstract] [Full Text] [Related]
5. [Supramolecular Agents for Theranostics].
Deyev SM; Lebedenko EN
Bioorg Khim; 2015; 41(5):539-52. PubMed ID: 26762091
[TBL] [Abstract][Full Text] [Related]
6. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
[TBL] [Abstract][Full Text] [Related]
7. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
Niwa R; Satoh M
J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
9. Multicolor imaging and the anticancer effect of a bifunctional silica nanosystem based on the complex of graphene quantum dots and hypocrellin A.
Zhou L; Zhou L; Ge X; Zhou J; Wei S; Shen J
Chem Commun (Camb); 2015; 51(2):421-4. PubMed ID: 25407475
[TBL] [Abstract][Full Text] [Related]
10. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
Fazekas-Singer J; Singer J; Jensen-Jarolim E
Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
[TBL] [Abstract][Full Text] [Related]
11. Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Carter PJ; Lazar GA
Nat Rev Drug Discov; 2018 Mar; 17(3):197-223. PubMed ID: 29192287
[TBL] [Abstract][Full Text] [Related]
12. Homogeneously modified immunoglobulin domains for therapeutic application.
Liu T; Du J; Luo X; Schultz PG; Wang F
Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
[TBL] [Abstract][Full Text] [Related]
13. Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges.
Du Y; Xu J
Adv Mater; 2021 Dec; 33(48):e2103114. PubMed ID: 34585802
[TBL] [Abstract][Full Text] [Related]
14. Current status of Cancer Nanotheranostics: Emerging strategies for cancer management.
Chavda VP; Khadela A; Shah Y; Postwala H; Balar P; Vora L
Nanotheranostics; 2023; 7(4):368-379. PubMed ID: 37151802
[TBL] [Abstract][Full Text] [Related]
15. Graphene oxide covalently grafted upconversion nanoparticles for combined NIR mediated imaging and photothermal/photodynamic cancer therapy.
Wang Y; Wang H; Liu D; Song S; Wang X; Zhang H
Biomaterials; 2013 Oct; 34(31):7715-24. PubMed ID: 23859660
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-based Cell Trackers for Biomedical Applications.
Ni JS; Li Y; Yue W; Liu B; Li K
Theranostics; 2020; 10(4):1923-1947. PubMed ID: 32042345
[TBL] [Abstract][Full Text] [Related]
17. Antibody fragments for controlled delivery of therapeutic agents.
Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
[No Abstract] [Full Text] [Related]
18. Bioinspired theranostic quantum dots: Paving the road to a new paradigm for cancer diagnosis and therapeutics.
Mazahir F; Sharma R; Yadav AK
Drug Discov Today; 2023 Dec; 28(12):103822. PubMed ID: 37949429
[TBL] [Abstract][Full Text] [Related]
19. [Progress in the study of Her2-targeted cancer therapeutic antibodies].
Chang L; Li CH; Gao J
Yao Xue Xue Bao; 2015 May; 50(5):516-20. PubMed ID: 26234129
[TBL] [Abstract][Full Text] [Related]
20. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging.
Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO
Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
